Royalty Pharma plc Interest Expense Nonoperating
Royalty Pharma plc (RPRX) reported Interest Expense Nonoperating of $93.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-05
- Royalty Pharma plc interest expense nonoperating for the quarter ending 2026-06-30 was $93.62M, a 36.33% increase year-over-year.
- Royalty Pharma plc interest expense nonoperating for the quarter ending 2026-03-31 was $93.72M, a 43.61% increase year-over-year.
- Royalty Pharma plc interest expense nonoperating for the quarter ending 2025-12-31 was $94.17M, a 43.20% increase year-over-year.
- Royalty Pharma plc interest expense nonoperating for the quarter ending 2025-09-30 was $79.56M, a 19.63% increase year-over-year.
- Royalty Pharma plc interest expense nonoperating for fiscal 2025 was $307.66M, a 36.43% increase from fiscal 2024.
- Royalty Pharma plc interest expense nonoperating for fiscal 2024 was $225.51M, a 20.47% increase from fiscal 2023.
- Royalty Pharma plc interest expense nonoperating for fiscal 2023 was $187.19M, a 0.41% decline from fiscal 2022.
- Royalty Pharma plc interest expense nonoperating for fiscal 2022 was $187.96M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $93.62M 10-Q · filed 2026-08-05 | $187.34M 10-Q · filed 2026-08-05 | $281.51M derived: sum of 3 quarters · filed 2026-08-05 | $361.07M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $93.72M 10-Q · filed 2026-05-06 | $187.89M derived: sum of 2 quarters · filed 2026-05-06 | $267.46M derived: sum of 3 quarters · filed 2026-05-06 | $336.13M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $94.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $173.74M derived: sum of 2 quarters · filed 2026-02-11 | $242.40M derived: sum of 3 quarters · filed 2026-08-05 | $307.66M 10-K · filed 2026-02-11 |
| 2025-09-30 | $79.56M 10-Q · filed 2025-11-05 | $148.23M derived: sum of 2 quarters · filed 2026-08-05 | $213.49M 10-Q · filed 2025-11-05 | $279.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $68.67M 10-Q · filed 2026-08-05 | $133.93M 10-Q · filed 2026-08-05 | $199.69M derived: sum of 3 quarters · filed 2026-08-05 | $266.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $65.26M 10-Q · filed 2026-05-06 | $131.02M derived: sum of 2 quarters · filed 2026-05-06 | $197.53M derived: sum of 3 quarters · filed 2026-05-06 | $246.54M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $65.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $132.27M derived: sum of 2 quarters · filed 2026-02-11 | $181.28M derived: sum of 3 quarters · filed 2026-02-11 | $225.51M 10-K · filed 2026-02-11 |
| 2024-09-30 | $66.51M 10-Q · filed 2025-11-05 | $115.52M derived: sum of 2 quarters · filed 2025-11-05 | $159.75M 10-Q · filed 2025-11-05 | $207.01M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $49.01M 10-Q · filed 2025-08-06 | $93.25M 10-Q · filed 2025-08-06 | $140.50M derived: sum of 3 quarters · filed 2026-02-11 | $186.53M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $44.23M 10-Q · filed 2025-05-08 | $91.49M derived: sum of 2 quarters · filed 2026-02-11 | $137.52M derived: sum of 3 quarters · filed 2026-02-11 | $184.47M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $47.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $93.29M derived: sum of 2 quarters · filed 2026-02-11 | $140.24M derived: sum of 3 quarters · filed 2026-02-11 | $187.19M 10-K · filed 2026-02-11 |
| 2023-09-30 | $46.03M 10-Q · filed 2024-11-06 | $92.98M derived: sum of 2 quarters · filed 2024-11-06 | $139.93M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $46.95M 10-Q · filed 2024-08-08 | $93.90M 10-Q · filed 2024-08-08 | ||
| 2022-12-31 | $187.96M 10-K · filed 2025-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |